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ttp://dx.doi.org/10.1016/j.ajpath.2012.12.006Myeloperoxidase (MPO) is a target antigen for antineutrophil cytoplasmic autoantibodies (ANCA). There
is evidence that MPO-ANCA cause necrotizing and crescentic glomerulonephritis (NCGN) and vasculitis.
NCGN severity varies among patients with ANCA disease, and genetic factors inﬂuence disease severity.
The role of genetics in MPO-ANCA NCGN severity was investigated using 13 inbred mouse strains, F1 and
F2 hybrids, bone marrow chimeras, and neutrophil function assays. Mouse strains include founders of
the Collaborative Cross. Intravenous injection of anti-MPO IgG induced glomerular crescents in >60% of
glomeruli in 129S6/SvEv and CAST/EiJ mice, but <1% in A/J, DBA/1J, DBA/2J, NOD/LtJ, and PWK/PhJ
mice. C57BL6J, 129S1/SvImJ, LP/J, WSB/EiJ, NZO/HILtJ, and C3H mice had intermediate severity.
High-density genotypes at 542,190 single nucleotide polymorphisms were used to identify candidate
loci for disease severity by identifying genomic regions that are different between 129S6/SvEv and
129S1/SvImJ mice, which are genetically similar but phenotypically distinct. C57BL/6  129S6 F2 mice
were genotyped at 76 SNPs to capture quantitative trait loci for disease severity. The absence of
a dominant quantitative trait locus suggests that differences in severity are the result of multiple gene
interactions. In vivo studies using bone marrow chimeric mice and in vitro studies of neutrophil
activation by anti-MPO IgG indicated that severity of NCGN is mediated by genetically determined
differences in the function of neutrophils. (Am J Pathol 2013, 182: 1219e1226; http://dx.doi.org/
10.1016/j.ajpath.2012.12.006)Supported by NIH NIDDK grant 2-P01-DK058335-11 (H.X., P.H.,
R.J.F., and J.C.J.).
H.X. and D.C. contributed equally to this work.
Portions of these data were presented at the annual meeting of the United
States and Canadian Academy of Pathology, March 20e26, 2010, Wash-
ington, DC, as Abstract 1549.Anti-neutrophil cytoplasmic autoantibodies (ANCA), in-
cluding ANCA speciﬁc for myeloperoxidase (MPO-ANCA),
are associated with systemic vasculitis and pauci-immune
necrotizing crescentic glomerulonephritis (NCGN), and there is
strong evidence that MPO-ANCA are pathogenic.1 NCGN is
induced in mice by injecting anti-MPO IgG,2e5 and is
mediated by neutrophils, enhanced by neutrophil priming,
modulated by Fc gamma receptor engagement, and requires
alternative complement pathway activation.2e7
Patients with ANCA disease have varied NCGN severity,
ranging from 100% to <5% crescents (average, 50%),8 and
a minority of patients have systemic small vessel vasculitis
with noglomerulonephritis.1 Evidence for genetic inﬂuenceon
ANCA-associated disease includes familial occurrences,9e13
greater frequency in ﬁrst-degree relatives,14 differences in
racial incidence,14e17 association betweendisease severity and
polymorphisms in genes that inﬂuence immune responses and
inﬂammation,18e28 and a genome-wide association study thatstigative Pathology.
.indicates genetically determined differences between disease
associated with MPO-ANCA versus proteinase 3especiﬁc
ANCA (PR3-ANCA).29
Intravenous injection of anti-MPO IgG into C57BL/6
(B6) mice induces NCGN with crescent formation in
approximately 5% to 10% of glomeruli in 100% of mice.2e7
To investigate the effect of genetic backgrounds on disease
severity, anti-MPO IgG was injected into 12 additional
mouse strains, which demonstrated substantial differences in
disease susceptibility and severity. High-density genotyping
was used to identify candidate loci for disease severity by
identifying genomic regions that are different between
Xiao et algenetically similar, but phenotypically distinct, sister strains.
F2 mice from a cross between low-severity B6 mice and
high-severity 129S6/SvEv (129S6) mice were genotyped to
identify quantitative trait loci (QTL) for disease severity.
In vivo studies using bone marrow (BM) chimeric mice and
in vitro studies of neutrophil activation by anti-MPO IgG
demonstrated that NCGN severity is mediated by geneti-
cally determined differences in neutrophil function.
Materials and Methods
Mice
C57B6/6J (B6), 129S6/SvEv (129S6), 129S1/SvImJ (129S1),
LP/J (LP), WSB/EiJ (WSB), NZO/H1LtJ (NZO), PWK/PhJ
(PWK), NOD/LtJ (NOD), DBA1, DBA2, AJ, C3H, and
CAST/Ei (CAST), C57BL/6J (B6) and LP/J (LP) mice were
purchased from Jackson Laboratories (Bar Harbor, ME).
129S6/SvEv (129S6), 129S1, Rag2 knockout with B6.SJL
background (Rag2/B6), and Rag2 knockout with 129S6/
SvEv background (Rag2/129S6) mice were purchased
from Taconic Farms (Germantown, NY). NOD/LtJ, NZO/
H1LtJ, PWK/PhJ, and WSB/EiJ were obtained from the
University of North Carolina Department of Genetics. MPO
knockout (Mpo/) mice were initially generated by Aratani
and colleagues.30 B6, 129S1, NOD, NZO, PWK, WSB,
CAST, and A/J strains are founders of the Collaborative
Cross31,32 and capture 90% of the genetic diversity among
laboratorymice. F1micewere generated byB6 backcrosswith
129S6 mice, and 100 F2 mice were generated by (B6X129S6)
F1 intercross. Mice were maintained by University of North
Carolina Division of Laboratory Animal Medicine in adher-
ence to the 2011 NIH Guide for Care and Use of Laboratory
Animals.
Preparation of Pathogenic Mouse Anti-Murine MPO IgG
Puriﬁcation of native mouse MPO and immunization of
Mpo/micewere performed as described.2Mpo/mice 8 to
10 weeks old were immunized intraperitoneally with 20 mg of
puriﬁed murine MPO in complete Freund’s adjuvant and
boosted twice with 10 mg of MPO in incomplete Freund’s
adjuvant. Anti-MPO was monitored by enzyme-linked immu-
nosorbent assay. Anti-MPO IgG was isolated from serum of
Mpo/ mice immunized with MPO by 50% ammonium
sulfate precipitation and protein G afﬁnity chromatography.2
Purity of antibodies was conﬁrmed by SDS-PAGE electro-
phoresis, and protein concentrations determined by Coomassie
protein assay (Pierce, Rockford, IL).
Induction of Glomerulonephritis with Anti-MPO IgG
Mice were injected intravenously with 50 mg/g bodyweight
mouse anti-mouse MPO IgG.2 After 6 days, mice were
sacriﬁced and kidneys examined by light microscopy for
NCGN. For BM transplantation experiments, 6 weeks after1220BM transfer, Rag2/ mice were injected intravenously
with 50 mg/g body weight of anti-MPO IgG and sacriﬁced
6 days later.
Pathological Evaluation
Kidneys were collected at the time of sacriﬁce and ﬁxed in
10% formalin, embedded in parafﬁn, sectioned at 4 mm,
stained with H&E and periodic acid Schiff, and then eval-
uated by light microscopy. The extent of glomerular cres-
cents and necrosis were expressed as mean % glomeruli
with crescents or necrosis by counting all glomeruli in cross
sections of both kidneys, which averaged approximately
80 per mouse. Glomerular leukocytes in kidneys from BM
chimeric mice were evaluated by immunohistochemistry on
parafﬁn sections.
BM Chimeras
BM cells were harvested from femurs and tibia of B6 and
129S6 mice, and erythrocytes removed by hypotonic lysis.7
Age-matched Rag2/B6 and Rag2/129S6 recipient
mice were kept under sterile conditions and given acidiﬁed
water with 0.2% neomycin at least 1 week before irradiation.
Recipients were lethally g-irradiated with 900 rad, and 12 to
24 hours later were reconstituted intravenouslywith 1.5 107
donor BM cells: 129/S6 donor cells into Rag2/B6 recipi-
ents (129S6/ Rag2/B6 chimeras), B6 donor cells into
Rag2/129S6 recipients (B6/ Rag2/129S6 chimeras).
Successful transplantation was conﬁrmed by ﬂow cytometry
measuring CD45.1 and CD45.2 (BD Pharmingen, San Jose,
CA), which distinguish leukocytes from recipients and
donors.
In Vitro Neutrophil Activation by Anti-MPO IgG
Superoxide dismutase (SOD)-inhibitable reduction of ferri-
cytochrome C was used to measure neutrophil oxidative
activity. Neutrophils were suspended at 1  107 in HBSS
buffer and pretreated with 5 mg/mL cytochalasin B for 15
minutes at 4C. Neutrophils (5  105, in HBSS) were
prewarmed with 50 mmol/L ferricytochrome with or without
300 U/mL SOD for 15 minutes at 37C and then primed
with 2 ng/mL tumor necrosis factor-alpha (TNF-a) for 15
minutes at 37C. Primed neutrophils were incubated with
250 mg/mL anti-mouse MPO IgG at 37C, and absorption of
samples was scanned at 550 nm every 5 minutes for 60
minutes using a Microplate Autoreader (Molecular Devices,
Sunnyvale, CA).
Comparative Genomic Evaluation
Genetic variation among mouse strains was determined by
comparing publically available high-density genotypes at
542,190 single nucleotide polymorphisms (SNPs) using
a mouse diversity array.33e36 Genomic clustering ofajp.amjpathol.org - The American Journal of Pathology









Anti-MPO Glomerulonephritisidentical genotypes was performed to identify regions
identical by descent (IBD). IBD was performed by counting
the number of identical SNPs in 100 SNP windows.
Windows with 98% genotype similarity were declared
IBD.36Strains numbers, n crescents, n present necrosis, n present
B6 27 27 9.5 27 4.0
129S6 24 24 63.7* 24 22.4*
129S1 22 22 21.1y 21 7.3y
LP 8 8 19.8 8 5.9
WSB 4 4 9.0 4 2.8
NZO 4 4 2.8 4 2.8
PWK 5 1 0.7 0 NA
NOD 4 0 NA 0 NA
DBA1 5 2 0.9 0 NA
DBA2 5 0 NA 0 NA
AJ 4 0 NA 0 NA
C3H 5 5 5.2 4 2.3
CAST 5 5 61.2 5 35.6
*P < 0.001 versus B6 and 129S1 mice.
yP > 0.4 versus LP mice.
NA, not applicable; no crescents or necrosis was observed.QTL Mapping
B6  129S6 F2 intercross was used to associate genetic
variants with NCGN phenotypes. Genomic DNA was iso-
lated from tails with a proteinase K/SDS lysis solution
followed by phenol-chloroform extraction. Ninety-nine
female F2 mice were genotyped at 76 SNPs using Seque-
nom iPEX MassARRAY (Sequenom, San Diego, CA) (1
of 108 samples was inadequate). The genetic map was
estimated using the R/qtl est.map function (R software;
http://www.r-project.org/)37,38 assuming genotyping error
of 0.001. Single-QTL interval mapping (IM) was performed
using the R/qtl scanone function on % crescents and log %
crescents. Log % crescents was distributed normally and IM
was performed using a normal model. % crescents was
mapped with a nonparametric IM model. A two-QTL model
was used for log % crescents using the R/qtl scantwo
function. Thresholds for both single- and two-QTL models
were determined by 1000 permutations.39Statistical Analysis
Tukey’s multiple comparison test was used for evaluating
differences in mean percent crescents between groups.Results
Survey of Mouse Strains Demonstrates Genetic Basis of
Severity of Anti-MPO NCGN
Mean % crescents induced by anti-MPO varied from 0% to
>60% in 13 mouse strains including 8 Collaborative Cross
founders that include 90% of the genetic diversity among
laboratory mice31,32 (Table 1 and Figures 1 and 2). 129S6/
SvEv (129S6) mice had 47 to 90% (mean 63.7%) compared
to 4 to 23% in B6 (mean 9.5%) (P < 0.001). 129S1 mice
developed an average of 21% crescents, which was a
signiﬁcant reduction (P < 0.001) compared to 129S6. LP/J
mice were included because they share ancestry with 129
mice33 and were found to have severity similar to 129S1
rather than 129S6. DBA1, DBA2, and C3H were included
because they have susceptibility to vasculitis in other
models. As shown in Figure 2 and Table 1, anti-MPO IgG
induced NCGN in WSB and C3H mice, similar to B6 mice.
CAST mice developed severe NCGN similar to 129S6.
NZO mice developed <5% crescents. Only a minority of
PWK and DBA1 mice developed crescents, affecting <1%
of glomeruli. NOD, AJ, and DBA2 mice were resistant to
NCGN induction.The American Journal of Pathology - ajp.amjpathol.orgComparative Genome Analysis of 129S6, 129S1, B6,
and LP Strains
129S6 and 129S1 have a signiﬁcantly different fraction of
glomeruli affected but are closely related, with most genetic
differences clustered.34,35 High-density genotypes were
compared between 129S6 and 129S1 strains (Table 2 and 3).
B6 and LP strains were also evaluated. The mouse diversity
array36,40 used for genotyping contains 542,190 SNPs. Of
these, 137,378 SNPs (25.34%) segregated among the four
strains. B6 differs from the other three strains at over 20% of
SNPs, LP differs from 129 at 7% to 8%, and the 129 sub-
strains differ from each other at <1% (Table 3).
We determined that the B6 strain is IBD with each of the
other three strains over 28% of the genome. The remaining
72% is a likely location of alleles associated with reduced
severity of NCGN. However, the IBD regions cannot be
eliminated as candidate regions that inﬂuence NCGN
phenotypes because genes within an IBD region could
interact with genes in non-IBD regions to inﬂuence disease.
More recent separation of the LP strain from the 129 sub-
strains resulted in a greater IBD fraction than for B6 (72% to
74%). The high degree of genetic similarity between 129S1
and 129S6 (>99% SNP matches) contrasted with striking
differences in NCGN severity. 129S1 and 129S6 are IBD at
96.7% of the genome (Table 2 and 3). The 3.3% non-IBD
fraction is conﬁned to 15 regions over 90.8 Mb on nine
chromosomes (Figure 3). These non-IBD regions contain
90% of mismatches between 129S1 and 129S6 (Table 2). In
these regions, the 129 substrains are as different from each
other as 129S6 is from B6 or LP, and 129S1 is from B6
(Table 3). 129S1 is IBD to LP across 8 of 15 regions (1, 2,
3, 5, 6, 11, 12, and 15; 56.0 Mb). Shared alleles in these
regions probably explain the similar phenotypes. 129S1 is1221
Figure 2 Severity of NCGN in 13 strains of mice and in B6  129S6 F1
and F2 mice, represented as the % of glomeruli with crescents. The two
groups of B6 mice received different antibody preparations.
Table 2 SNP Genotypes in IBD and Non-IBD Regions between
129S1 and 129S6
IBD Non-IDB
Total mismatches 460 4048
Fraction of mismatches 10.20% 89.80%
Fraction of genome 96.69% 3.31%
Frequency of mismatches 0.09% 22.85%
Figure 1 Photomicrographs demonstrating less severe NCGN caused by
anti-MPO IgG in a B6 mouse, with an arrow showing one of three glomeruli
with a crescent, compared to a 129S6 mouse, with arrows pointing to
crescents in four of four glomeruli and a background of secondary tubu-
lointerstitial changes (H&E stains).
Xiao et alIBD to B6 in region 10 (1.0 Mb) and is nearly identical in
regions 6 (11.7 Mb) and 1a (3.3 Mb). By contrast, 129S6 is
identical to B6 and LP only in regions 14 (1.2 Mb) and 4
(2.9 Mb) and is completely divergent across other regions.
These 15 regions (Figure 3), which contain 761 known
genes (Supplemental Table S1), are candidates for loci
mediating differences in NCGN between 129 substrains.
Linkage Analysis of C57BL/6  129S6 F2 Intercross
Female F1 mice produced by crossing B6 and 129S6 mice,
and female F2 mice produced by intercrossing F1 mice, were
injected with anti-MPO IgG. F1 mice (nZ 9) developed an
average of 13.6% crescents, and F2 mice (n Z 100)
developed a wide range of NCGN severity with clustering at
lesser severity, more like B6 than 129S6 (Figure 2).
The F2 intercross population was genotyped at 76 SNPs
to capture quantitative trait loci (QTL) for disease severity.
Suggestive QTL peaks were observed for log-transformed
% crescents on Chromosomes 4, 5, 7, 9, and 10; however,
no QTL peaks reached sufﬁcient genome-wide signiﬁcance,1222as calculated for 5% and 10% error thresholds. Suggestive
QTL on Chromosome 4 and Chromosome 9 do not include
129S6-129S1 non-IBD regions, thus these regions may
contain alleles that explain differences between B6 and
129S6. The suggestive QTL on Chromosome 5, 7, and 10
each span regions that have signiﬁcant divergence between
129 substrains. Based on this linkage analysis, differences in
disease severity are likely to result from multiple gene
interactions, and may involve epistasis.
BMeDerived Cells Mediate Genetic Differences in
Severity between Strains
To determine whether differences in NCGN severity
between B6 and 129S6 resulted from differences in function
of BM-derived cells, BM chimeric mice were produced.
Rag2/ B6 or Rag2/ 129S6 mice were lethally irradiated
followed by intravenous injection of 129S6 or B6 BM,
respectively, resulting in chimeras that had B6 bodies with
129S6 BM, or 129S6 bodies with B6 BM. Engraftment of
hematopoietic cells was conﬁrmed by ﬂow cytometric
measurement of % recipient common leukocyte antigen
(CD45.1 or CD45.2) positive peripheral blood leukocytesajp.amjpathol.org - The American Journal of Pathology
Table 3 Comparative Genotype Analysis Using the Mouse Diversity Array
129S6 vs B6 129S6 vs 129 S1 129S6 vs LP/J 129S1 vs LP/J 129S1 vs B6 B6 vs LP/J
Genome wide
Number of mismatches 115,069 4508 41,949 38,908 114,567 116,926
Percentage of mismatches 21.22% 0.83% 7.74% 7.18% 21.13% 21.57%
Percentage of matches 78.78% 99.17% 92.26% 92.82% 78.87% 78.43%
Percentage of IBD* 27.42% 96.69% 72.16% 74.43% 28.04% 27.99%
129S6 and 129S1 non-IBDy
Number of mismatches 4075 4048 3931 1100 3641 3481
Percentage of mismatches 23.01% 22.85% 22.19% 6.21% 20.56% 19.56%
Six pairwise genotype comparisons of four inbred mouse strains were performed at 542,190 SNPs distributed across the genome to assess the extent of
genetic relatedness.
*The fraction of the genome that was deﬁned as identical by descent (IBD) between any two strains was determined by calculating the percentage of those
two genomes with 98% or greater identity over windows of 100 SNPs.
yThe regions of the genome that were non-IBD between 129 S6 and 129 S1 contained 17,713 SNPs of the Mouse Diversity Array. Pairwise genotype comparisons
of the four inbred mouse strains were performed at these 17,713 SNPs to assess the genetic relatedness within the 129 S6 and 129 S1 non-IBD regions.
Anti-MPO Glomerulonephritis(PBL) and % donor CD45 positive PBL. Four weeks after
irradiation and transplantation, >95% of PBL were donor
derived. Anti-MPO was administrated intravenously 4
weeks after BM transfer, and 6 days later, NCGN was
assessed. Rag2/ B6 mice (n Z 4) transplanted with
129S6 BM developed 79% crescents (69% to 85%), which
is similar to Rag2/ 129S6 mice (Figure 4). Rag2/129S6
mice (n Z 6) that received BM from B6 mice had 17%
crescents (9% to 22%) similar to Rag2/ B6. Immuno-
histochemical staining for neutrophils and macrophages
demonstrated more neutrophils in glomeruli of B6 mice
with 129S6 BM compared to 129S6 mice with B6 BM,
although there was no difference in macrophages (Table 4).
Thus, genetically determined characteristics of BM-derived
cells are responsible for the marked differences in disease
between B6 and 129S6 mice, and this is associated with
glomerular neutrophil inﬁltration.
Genetically Determined Differences in Activation of
Neutrophils by Anti-MPO
Neutrophils were primed with TNF-a, incubated with anti-
MPO IgG, and superoxide generation was then measured.Figure 3 The 3.3% non-IBD fraction is conﬁned to 15 regions over 90.8
Mb on nine chromosomes. In the regions in which 129S1 and 129S6 are
genetically identical, the blue and red lines are close together, whereas in
divergent regions, they are farther apart.
The American Journal of Pathology - ajp.amjpathol.orgAnti-MPO IgG caused more activation of neutrophils from
129S6 compared to neutrophils from B6 or 129S1 mice
(Figure 5), which correlated with NCGN severity in these
strains (Table 1 and Figure 2), and demonstrated that genetic
differences inﬂuence neutrophil activation by anti-MPO.
Discussion
Differences in severity of NCGN induced by anti-MPO IgG
among mouse strains indicate that severity is genetically
determined and that there are either protective alleles in less
affected strains, or severity alleles in more severely affected
strains. Because 129S6  B6 F1 mice exhibit less severe
NCGN than 129S6, either some or all B6 alleles are
protective and have a dominant mode of inheritance, or
129S6 severity alleles are recessive. NCGN phenotypes in
129S6  B6 F2 mice span the extremes seen in 129S6 and
B6 strains, suggesting that NCGN induced by anti-MPO is
a polygenic trait.
Comparative genome analysis using the mouse diversity
array revealed differences in genomic architecture under-
lying differences in NCGN phenotypes among four inbredFigure 4 BM chimeric mice were created by transplanting (Tx) 129S6 or
B6 BM into lethally irradiated Rag2/ B6 or Rag2/ 129S6 mice,
respectively. The severity of glomerulonephritis induced by anti-MPO IgG
was determined in the BM chimeras and the corresponding nonchimeric
donor strains. The severity of crescent formation corresponded with the BM
genotype, not the somatic genotype.
1223






% Gloms with crescents 79.29  7.14% 17.00  4.77%
% Gloms with neutrophils 84.13  4.17% 21.5  8.95%
Neutrophils per glom 3.15  0.30 0.38  0.17
% Gloms with macrophages 6.25  1.89% 5.0  1.63%
Macrophages per glom 0.07  0.03 0.05  0.02
Neutrophils and macrophages were detected by immunohistochemistry.
Gloms, glomeruli.
Figure 5 In vitro activation by anti-MPO IgG of neutrophils. Neutro-
phils from B6 (black circles), 129S6 (black triangles), and 129S1 (black
squares) mice were primed with TNF-a, incubated with murine anti-MPO
IgG, and superoxide generation was measured as an indicator of neutro-
phil activation. Negative control experiments included neutrophils from B6
(white circles), 129S6 (white triangles), and 129S1 (white squares), all
treated with TNF-a, but no anti-MPO IgG.
Xiao et alstrains. This comparison demonstrated that genomes of 129
substrains do not contain uniformly distributed de novo
mutations acquired since the strains split; instead, their
genomes are highly divergent over discrete regions. Genes
responsible for difference in NCGN phenotype between the
129 substrains may be in the 90.8 Mb that differs between
these substrains. However, it is also possible that genetic
interactions between loci in IBD and non-IBD regions
inﬂuence disease severity. Linkage analysis planned for the
future in an F2 population between 129S6 and 129S1 mice
could address this possibility; moreover, linkage analysis of
an S6eS1 F2 intercross, or backcross, would simplify
genetic architecture within the mapping population and
increase the power to detect variants associated with NCGN
in the 15 candidate regions. De novo mutation could account
for differences between 129S1 and 129S6; however, de
novo mutation could not be assessed without 129S6
genomic sequence.
Several of these 761 known genes in the non-IBD frac-
tion of 129S1 and 129S6 (Supplemental Table S1) are
particularly interesting based on previous studies on the
pathogenesis of ANCA disease,1-7 including genes involved
in antibodyecell surface interaction, epigenetic gene regu-
lation, complement activation, Fc receptor engagement, and
cell signaling. Given the evidence for an important role for
FcgR in the pathogenesis of ANCA disease,41e47 it is
interesting that there are multiple Fc receptor genes in the
129S6/129S1 non-IBD regions: Fc gamma receptor 1 gene
(Fcgr1) in region 2 on Chromosome 3, and Fc receptor-like
5 (Fcrl5), Fc receptor-like 1 (Fcrl1), and Fc receptor-like
scavenger (Fcrls) in region 2 on Chromosome 3.
F2 intercross between B6 and 129S6 was used to inves-
tigate genetic factors affecting NCGN severity. The NCGN
phenotypes in 129S6  B6 F2 mice span the range seen in
129S6 and B6, suggesting that NCGN induced by anti-MPO
IgG is a polygenic trait. A signiﬁcant QTL was not detected,
suggesting complex genetic architecture, possibly involving
epistasis. However, multiple suggestive peaks were ob-
served, three of which spanned non-IBD regions between
the 129 substrains. Suggestive QTL peaks were observed
for log-transformed % crescents on Chromosomes 4, 5, 7, 9,
and 10; however, no QTL peaks reached sufﬁcient genome-
wide signiﬁcance, as calculated for 5% and 10% error
thresholds. The suggestive regions on Chromosome 5 and1224Chromosome 7 are the second and third largest genomic
regions of divergence, spanning 26 Mb. Two genes in-
volved in epigenetic histone modiﬁcations reside on Chro-
mosome 7: Eed, a component of the Polycomb repressive
complex 2 (PRC2) that methylates H3K27, and Mll4, an
H3K4 methyltransferase. Dysregulated expression of ANCA
autoantigen genes occurs in neutrophils of ANCA disease
patients,48e50 and is associated with disrupted epigenetic
silencing via histone methylation of autoantigen genes.50
This overlap between a non-IBD region, a suggestive QTL,
and a transcriptional regulatory mechanism for ANCA
autoantigen genes is intriguing and will be studied further.
The absence of a signiﬁcant QTL for NCGN severity in
our model differs from the identiﬁcation of QTL in other
rodent models of crescentic glomerulonephritis.51,52 An
important distinction is that these studies investigated disease
susceptibility, whereas our study investigated severity. More
importantly, both of these models have either a more com-
plex interplay of multiple pathogenic processes in addition to
ANCA-mediated injury51 or a different pathogenic process
that does not involve ANCA.52 The most relevant model to
ours is induced inWistar Kyoto (WKY) rats by immunization
with human MPO, which results in anti-MPO antibodies that
cross-react with rat MPO and cause NCGN.53 Unlike WKY
rats, Lewis, Wistar Furth, and Brown Norway rats immu-
nized with human MPO do not develop NCGN, even though
they develop comparable levels of anti-MPO to WKY rats.
We hypothesized that this strain difference was more likely
caused by genetically determined differences in the innate
immune response rather than a difference in the adaptive
immune response. This is in agreement with the ﬁndings in
our study that show that identical injections of anti-MPO IgG
into different mouse strains induce very different degrees of
NCGN, thus implicating difference in innate immunity rather
than adaptive immunity as the basis for the differences in
pathogenesis.ajp.amjpathol.org - The American Journal of Pathology
Anti-MPO GlomerulonephritisConclusion
The severity of anti-MPOeinduced NCGN in this mouse
model is genetically modulated, and this genetic inﬂuence
acts through modulation of responsivity of neutrophils to
activation by ANCA. Linkage analysis suggests that this is
a complex polygenic trait. Additional studies will be
required to identify the genes and regulatory mechanisms
responsible for this modulation. These genes and gene
products may have important roles in pathogenesis of
human ANCA disease, and could be markers of disease
activity and outcome, as well as targets for therapy.Acknowledgments
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